TARO Taro Pharmaceutical Industries Ltd.

Taro Announces Joining of CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today that Mr. Uday Baldota has joined the Company as its Chief Executive Officer (“CEO”) effective August 28, 2017. Since December 2016, Mr. Baldota has served as a member of Taro’s Board of Directors (“Taro Board”).

Mr. Baldota replaces Mr. Abhay Gandhi, who served in the role of Interim Chief Executive Officer since January 1, 2017. Mr. Gandhi will continue in his role as Vice Chairman of the Taro Board and as the CEO of the Sun Pharma North America operations.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

EN
01/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taro Pharmaceutical Industries Ltd.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

U.S. Dollar (DXY) Rolling Over Large-cap indexes (S&P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs. Mid-caps (S&P 400, Russell Mid-Cap) are starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps, and are likely to break out from their 2.5-month consolidations/high bas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Staples and Health Care to Market Weight As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024. Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume. This includes areas such as Technology (XLK), semiconductors (SMH), software (IGV), and the ARKK, IPO, and BITQ ETFs. This tells us a pause/pullback is likely...

 PRESS RELEASE

Taro to Announce Full Year Results on May 17, 2018

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2018, on Thursday, May 17, 2018. The Company will conduct an earnings call at 8:00 am EDT on Friday, May 18, 2018, where senior management will discuss the Company’s performance and answer questions from participants. The release will be accessible on Taro’s website at www.taro.com. Earnings Call (8:00 am EDT on Friday, May 18, 2018)...

 PRESS RELEASE

Taro Provides Results for December 31, 2017

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2017. Quarter ended December 31, 2017 Highlights ─ compared to December 31, 2016 Net sales of $155.5 million decreased $64.9 million, the result of continuing increased competition and the challenging pricing environment, particularly in the U.S.; despite an increase in overall volumes. ...

 PRESS RELEASE

Taro to Announce Third Quarter Results on February 7, 2018

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2017, after the close of market on Wednesday, February 7, 2018. The release will be accessible on Taro’s website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch